EIDX Eidos Therapeutics Inc

EXPLANATORY NOTE

This Amendment No. 7 amends the Schedule 13D, filed with the U.S. Securities and Exchange Commission by BridgeBio Pharma, Inc. (the “Reporting Person”) and its predecessor and wholly-owned subsidiary, BridgeBio Pharma LLC, relating to the Common Stock, par value $0.001 per share (the “Common Stock”), of Eidos Therapeutics, Inc., a Delaware corporation (the “Issuer”), whose principal executive offices are located at 101 Montgomery Street, Suite 2550, San Francisco, California 94104. Except as specifically set forth herein, the Schedule 13D remains unmodified.

Item 4. Purpose of Transaction.

Item 4 of the Schedule 13D is supplemented by the addition of the following:

On October 14, 2019, the Reporting Person issued a press release (the “Press Release”) announcing that the Reporting Person had terminated its previously announced proposal to acquire all of the outstanding shares of Common Stock of the Reporting Person that it did not already own and would no longer be pursuing the proposed transaction with the Issuer at this time. A copy of the Press Release is filed herewith as Exhibit 4, and the information set forth in the Press Release is incorporated by reference herein.

As previously reported, the Reporting Person previously acquired the securities described in this Schedule 13D for investment purposes and the Reporting Person intends to review its investments in the Issuer on a continuing basis.

The Reporting Person may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, including, but not limited to, in the open market, block sales or in privately negotiated transactions. In addition, the Reporting Person and Related Persons, including Dr. Kumar and Mr. Satvat may engage in discussions with management, the Issuer’s board of directors, and shareholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or take-private transaction that could result in the de-listing or de-registration of the Common Stock; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer’s business or corporate structure, including changes in management or the composition of the board of directors.

Any actions the Reporting Person might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Person’s review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; price levels of the Issuer’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

Other than as described above, the Reporting Person does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Person may change its purpose, change its intentions with respect to previous plans or formulate different plans or proposals with respect thereto at any time.

Item 5. Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is amended by restating the items disclosed under (a) – (b) thereof as follows:

BridgeBio Pharma, LLC, a wholly-owned subsidiary of the Reporting Person, is the record holder of 24,575,501 shares of Common Stock. The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 37,440,348 shares of Common Stock outstanding, calculated based on the 36,884,175 shares of Common Stock outstanding as of July 30, 2019, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed on August 1, 2019, plus the additional 556,173 shares of Common Stock issued on September 9, 2019, as reported in the Issuer’s Current Report on Form 8-K, filed on September 11, 2019.

Item 7. Material to be Filed as Exhibits.

Item 7 is amended and supplemented by adding the following at the end thereof:

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 15, 2019